Clinical Trial Update: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study results are posted for a Bendamustine, Obinutuzumab, and Venetoclax regimen in patients with untreated Mantle Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Emory University | Conditions: CCND1 Positive, Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-06